Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantationBruno Paiva, Jesús F. San Miguel, María‐Belén Vídriales et al.|Blood|2008Cited by 479
The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patientsBruno Paiva, María‐Belén Vídriales, Gema Mateo et al.|Blood|2009Cited by 75
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA RegistryClaudia Sargas, Pilar Martínez‐Sánchez, Elena Soria et al.|Cancers|2023Cited by 30
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA RegistryJorge Labrador, David Martínez‐Cuadrón, Blanca Boluda et al.|Cancer|2024Cited by 5
Clinical impact of FLT3 microclones on outcomes in patients with newly diagnosed FLT3-ITD negative AML: A subanalysis from the pethema quiwi trialClaudia Sargas, Pau Montesinos, Augustin Boudry et al.|Blood|2025Cited by 3